Next, to further investigate whether FAM225A level was correlated with the sensitivity of HCC cells to sorafenib treatment, the HepG2 cells insensitive to sorafenib (named as HepG2/SOR) were generated from HepG2. Here, FAM225A is linked to hepatocellular carcinoma.